Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
Covid: New breath test could detect virus in seconds
https://www.bbc.co.uk/news/amp/uk-wales-54718848
Covid: New breath test could detect virus in seconds
And could be used at airports.
https://www.bbc.co.uk/news/amp/uk-wales-54718848
https://www.bbc.co.uk/news/amp/health-54661843
However, there is uncertainty here. The virus was able to spread with ease last spring and cases, while remaining low, did start increasing again over the summer.
"A third wave is certainly possible," says Prof Woolhouse. "And if neither the second nor the third waves are anything like big enough to induce herd immunity, and we don't have a vaccine, then a fourth wave is possible.
"I don't think it will settle down at all in the next 18 months."
https://www.bbc.co.uk/news/amp/health-54661843
"A third wave is certainly p5ossible," says Prof Woolhouse. "And if neither the second nor the third waves are anything like big enough to induce herd immunity, and we don't have a vaccine, then a fourth wave is possible.
"I don't think it will settle down at all in the next 18 months."
From Hyves RNS
Following the decision to cancel the Shoptalk 2020 in-person event in Las Vegas, we are pleased to announce the launch of a new and ground-breaking virtual event which will be held online in Q1 of FY21.
Shoptalk's Retail Meetup is a new form of virtual event that will focus on connecting customers with both existing and new contacts. The Group expects to facilitate tens of thousands of meetings for more than 2,000 participants.
The event, which will be a proof-of-concept opportunity for the Group, builds upon Shoptalk's highly successful Hosted Retailers & Brands Program in a virtual format, bringing together established retailers and brands, direct-to-consumer and tech start-ups, large tech companies, venture capital investors, real estate developers, equity analysts, media and others for a broad range of interactions and meetings.
https://www.42gears.com/blog/6-wearable-technologies-you-must-know-right-now/
Smartwatches
Smartwatches are likely the most commonly-known and most commonly-used wearables in the workplace today. Connecting a smartwatch to a smartphone enables the wearer to read and send new messages from their watch, eliminating the need to hold and view one’s phone. Smartwatch designers are finding new ways to innovate: starting from its Series 4 product line, Apple’s Apple Watch enables users to obtain an electrocardiogram heart reading without any additional accessories, while the Matrix PowerWatch Series 2 can charge from solar power and body heat in place of electricity.
Why you need to know about smartwatches: As an increasingly common accessory, smartwatches can be a distraction in the workplace; even if workers’ smartphones are stowed away during a meeting, workers can read the news and communicate with each other using their smartwatches. Additionally, given that smartwatches run on their own operating systems, businesses will need to consider how to account for smartwatch software in managing their networks.
Smart Jewellery
Smart jewelry is the logical conclusion of ongoing research into how to include health-tracking capabilities in smaller wearables. The most prominent kind of smart jewelry (as of 2020) might be the smart ring. Exemplified by brands such are Oura, smart rings are worn on the finger like standard rings, all the while obtaining health-tracking data that the user can later review on a smartphone. Many other unique iterations of smart jewelry exist, from bangles to bracelets, with some designs even created by well-known fashion firms. In the near future, the Joule will expand the range of potential smart jewelry; a smart health-tracking device that doubles as an earring backing, Joule effectively allows any earring to become a smart device.
Enterprises may see wearables appearing more and more often in their workplaces in the near future, and, therefore, need to consider whether they might be able to leverage these technologies to create a more productive and connected workplace.
Read on to learn about six types of wearables that are likely to appear in your workplace in the coming years, and why they are important for you to know
In our clinical trials going forward, we are also planning to collect data on volunteer's via wearables during clinical trials. Therefore, Open Orphan's data, which may yield valuable digital biomarkers, could be one of the more sought-after datasets by many of the large wearables /smart watch wearables providers around the world.
Does this mean more OPEN ORPHAN STUDIES?
https://www.ft.com/content/2782655a-0441-4d38-bb03-5c4e67ead110
Scientists warn of new coronavirus variant spreading across EUROPE.
Scientists warn of new coronavirus variant spreading across Europe
Genetic mutation
that originated in Spain transmitted by returning holidaymakers, researchers find 5 57
Perhaps Pfizer would be advisable to contact OPEN ORPHAN and ask to do Challenge study?
Financial Times
Pfizer Inc
Pfizer urges patience in ‘last mile’ of Covid-19 vaccine process.
Pharmaceutical group’s timeline for first look at whether its trial works slips into November
Pfizer says it will have 15m doses of its vaccine ready for people in the US by the end of the year, if it is approved © REUTERS
Hannah Kuchler in New York YESTERDAY
Be the first to know about every new Coronavirus story.
Pfizer’s chief executive has urged patience in the “last mile” of Covid-19 vaccine development, after the timeline for an early look at whether a late-stage trial shows its vaccine works was poised to slip into November.
Albert Bourla said on Tuesday that he was still “cautiously optimistic” about the vaccine, which could be the first submitted for US emergency approval. He noted that “stress levels” around the world were rising as the “worst fears” come true, with Covid-19 spreading in Europe, the US and around the globe.
But the trial — which has enrolled over 42,000 participants, with 36,000 having received their second dose — has not yet hit the threshold at which it is allowed to do an initial analysis on whether the vaccine works.
“Let’s all have the patience that is required for something so important for public health and the global economy,” Mr Bourla told analysts on Tuesday.
Once the independent advisers do see the data and examine whether the rates of Covid-19 infection were higher in the placebo group than the vaccinated participants, he said it would take five to seven days for it to be analysed and published. Previously, Mr Bourla has said Pfizer could see the data before the end of October.
This is going to be not a Republican vaccine or a Democratic vaccine, it will be a vaccine for the citizens of the world
Albert Bourla, Pfizer chief executive
Vamil Divan, senior biopharmaceuticals research analyst at Mizuho, said it looked unlikely that Pfizer would publish this data until next week or later. He said unless participants develop Covid-19 — either on the placebo or on the vaccine — there was no way to determine if it worked.
Currently, the trial had not yet reached the 32 infections required for the initial efficacy analysis, Mr Bourla said.
Open Orphan's (LON:ORPH) Cathal Friel talks to Proactive London after publishing their six months results - which he says reveal they are 'on target to be profitable' and plans to end year 'with substantially more cash'.
Cash and cash equivalents at half year end were £14.7m with revenue of £7.1m, with a continued focus on delivering larger contracts.
Friel also talks through the £4.3 million contract with a global top ten vaccine company that was revealed earlier in the week.
Someone's trying to push this down!
And he hints on 'advanced negotiations with various parties' for a Coronavirus challenge study in the UK
https://www.proactiveinvestors.co.uk/companies/news/930292/open-orphan--on-target-to-be-profitable--and-plans-to-end-year--with-substantially-more-cash--930292.html
But it is profitable soon!
https://www.proactiveinvestors.co.uk/companies/news/930292/open-orphan--on-target-to-be-profitable--and-plans-to-end-year--with-substantially-more-cash--930292.html
Open Orphan 'on target to be profitable' and plans to end year 'with substantially more cash'
2020-09-30 07:12:00
Most stock shares have dropped today because of Covid 19!
Top up while you can.
https://uk.finance.yahoo.com/news/stock-market-report-28-october-covid-19-coronavirus-us-election-083941744.html
Most shares have fallen today because of the Covid 19!
https://uk.finance.yahoo.com/news/stock-market-report-28-october-covid-19-coronavirus-us-election-083941744.html
French President Emmanuel Macron speaks after meeting with the medical staff of the Rene Dubos hospital centre, in Pontoise, outside Paris. Photo: Ludovic Marin, Pool via AP
Global stock markets looked set for a day of heavy selling on Wednesday, as anxieties around the worsening COVID-19 second wave in Europe and the upcoming US election continue.
COVID-19 cases and deaths continue to rise across most of Europe. New restrictions now look set to ramp up across France and Germany, continental Europe’s two biggest economies.
“France and Germany look set to move towards some form of ‘lockdown lite’ over the next 24-48 hours with more info likely today and tomorrow,” Jim Reid, a senior strategist at Deutsche Bank, wrote in a note to clients on Wednesday morning.
Stock markets across Europe suffered heavy losses at the start of trade, falling to levels not seen since the depth of the first COVID-19 wave.
Watch: What are negative interest rates?
French president Emmanuel Macron is set to hold a televised address on Wednesday evening, French language news website The Local France reported. France24 reported that Macron was likely to announce new restrictions that could include a full lockdown on weekends or full lockdowns in the worst hit areas.
In Germany, Angela Merkel is set to meet with regional leaders to discuss tighter restrictions. Reports suggest she favours a “light lockdown,” but one that would still require the widespread closure of non-essential businesses.
READ MORE: Germany braces for 'lockdown light' as coronavirus cases keep climbing
European stock markets sunk deep into the red on Wednesday morning. The FTSE 100 (^FTSE) fell 1.8% in London, hitting its lowest point since April.
The FTSE 100 fell to a six month low. Photo: Yahoo Finance UK
The FTSE 100 fell to a six month low. Photo: Yahoo Finance UK
The DAX (^GDAXI) dropped 2.8% in Frankfurt and the CAC 40 (^FCHI) lost 2.7% in Paris. In Milan, the FTSE MIB (FTSEMIB.MI) fell by 2.4%. The IBEX 35 (^IBEX) lost over 1.8% in Madrid. All indexes were at levels not seen since May.
“Companies which just about scraped through in the spring may not survive another period without any business despite the generous state support which has been announced,” said Russ Mould, investment director at stockbroker AJ Bell.
Shares in retailers, restaurants, and travel stocks fell. Digital businesses like online supermarket Ocado (OCDO.L) and meal kit delivery service Hello Fresh (HFG.DE) were among the few winners.
Democratic presidential candidate former Vice President Joe Biden greets supporters during a drive-in rally at Cellairis Amphitheatre in Atlanta, Tuesday, Oct. 27, 2020. Photo: AP Photo/Andrew Harnik
Futures pointed to a sell-off at the open on Wall Street. S&P 500 futures (ES=F) were dow
The Imperial College London team found the number of people testing positive for antibodies has fallen by 26% between June and September.
https://www.bbc.com/news/health-54696873
https://www.google.com/amp/s/www.rt.com/russia/501068-russia-covid-two-strains/amp/
The world has thousands of Covid-19 strains, but 99% of all Russian cases come from just two, says health watchdog. So mutations will need more vaccines and more HUMAN CHALLENGE STUDIES /TRIALS to keep on top of this virus. It isn't going go away!
Mexico and possibly others use Human trials being to gain access to Vaccines!
https://www.ft.com/content/8beceb2f-14b1-4071-9283-0307159feff2
October 26, 2020 11:00 am by Jude Webber in Mexico City and Carolina Pulice in São Paulo?
Mexico has agreed to host human trials of seven Covid-19 vaccines to strengthen relations with pharmaceutical companies in case limited production capacity leads to a battle for doses.
“We are saving places in the queue for the purchase of something that does not yet exist,” said Martha Delgado, a deputy foreign minister, who has led Mexico’s efforts to secure vaccines. “You cannot wait to see it before getting in line?.?.?.?there is a risk some countries will say ‘this is all for me’,” she told the Financial Times in an interview.
Mexico’s willingness to host phase 3 trials reflects wider concerns among many middle- and lower-income countries that they could struggle to secure sufficient vaccine doses once a Covid-19 shot is finally approved for use
Regards Human challenge studies. The government wouldn't abandon these.
And to improve further its safety.
https://www.gov.uk/government/speeches/coronavirus-debate-opening-speech
We are contributing £33 million to back these trials, joining forces with academia and industry.
What a human challenge trial involves is taking a vaccine candidate that has proven to be safe in trials, and giving it to a carefully selected small number of healthy adult volunteers who are then exposed to?the?virus in a safe and controlled environment, closely monitored by medics and scientists.
And that gives us the chance to accelerate the understanding of promising vaccines that have been through clinical trials, so we can improve on their safe deployment.
And the UK is one of the only countries in the world with the capability to run this kind of programme.
And we should all be proud that once again we are leading this global effort.
I'm new to this board! What's all the talk about regards Eli Lili about? Why have they only got 26 days left? And what are they buying etc?
That is the way of having thinking regards the need for more OO because some diseases which were untreatable in the past will be treatable because of the new vaccine techniques being developed. Although I'm not an expert, but it stands to logic there will be advancements.
Human Challenge studies Matt Hand****
https://www.gov.uk/government/speeches/coronavirus-debate-opening-speech
We are contributing £33 million to back these trials, joining forces with academia and industry.
What a human challenge trial involves is taking a vaccine candidate that has proven to be safe in trials, and giving it to a carefully selected small number of healthy adult volunteers who are then exposed to?the?virus in a safe and controlled environment, closely monitored by medics and scientists.
And that gives us the chance to accelerate the understanding of promising vaccines that have been through clinical trials, so we can improve on their safe deployment.
And the UK is one of the only countries in the world with the capability to run this kind of programme.
And we should all be proud that once again we are leading this global effort.